How GLP-1 Drugs and SGLT2 Inhibitors Protect the Heart and Kidneys
GLP-1 receptor agonists and SGLT2 inhibitors protect cardiovascular and renal health through largely indirect mechanisms, with GLP-1 RAs targeting atherosclerosis and SGLT2i targeting heart failure and kidney function.
Quick Facts
What This Study Found
GLP-1 RAs and SGLT2i protect cardiovascular and renal systems through distinct but complementary mechanisms: GLP-1 RAs reduce atherosclerotic events while SGLT2i reduce heart failure and preserve kidney function.
Key Numbers
GLP-1RA: reduced MACE, MI, stroke; SGLT2i: reduced HF, preserved eGFR; low cardiac receptor expression; mortality reduced
How They Did This
Comprehensive mechanistic review of cardiovascular and renal outcome trial data with analysis of molecular mechanisms of GLP-1 RAs and SGLT2 inhibitors.
Why This Research Matters
These drugs have transformed diabetes care by offering organ protection beyond blood sugar control. Understanding their mechanisms helps optimize treatment selection and supports their expansion to non-diabetic patients with cardiovascular or kidney disease.
The Bigger Picture
The discovery that diabetes drugs can protect the heart and kidneys independent of blood sugar control has been one of the most important developments in medicine in recent years. Understanding the mechanisms is driving their use far beyond diabetes — into heart failure, chronic kidney disease, and potentially other conditions.
What This Study Doesn't Tell Us
Review limited to mechanisms known at time of publication. Exact mechanisms remain incompletely understood. Head-to-head comparisons between the two classes are limited.
Questions This Raises
- ?Would combining GLP-1 RAs and SGLT2i provide additive cardiovascular and renal protection?
- ?What other organ systems might benefit from these drug classes?
- ?Are the cardiovascular benefits class effects or drug-specific?
Trust & Context
- Key Stat:
- Complementary organ protection GLP-1 RAs reduce atherosclerotic events; SGLT2i reduce heart failure and kidney decline — different but additive benefits
- Evidence Grade:
- Comprehensive mechanistic review synthesizing data from multiple large cardiovascular and renal outcome trials. High-quality evidence base.
- Study Age:
- Published in 2021, reflecting the expanding indications for both drug classes beyond diabetes.
- Original Title:
- Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
- Published In:
- Med (New York, N.Y.), 2(11), 1203-1230 (2021)
- Authors:
- Cherney, David Z I(7), Udell, Jacob A(3), Drucker, Daniel J(11)
- Database ID:
- RPEP-05319
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do GLP-1 drugs protect the heart differently from SGLT2 inhibitors?
GLP-1 receptor agonists mainly reduce heart attacks and strokes by fighting atherosclerosis (plaque buildup in arteries). SGLT2 inhibitors mainly prevent heart failure and protect kidney function by altering how the kidneys handle fluid and blood flow. Together, they cover different aspects of cardiovascular and renal protection.
Do you need to have diabetes to benefit from these drugs?
Not necessarily. SGLT2 inhibitors are now approved for heart failure and chronic kidney disease in people without diabetes. GLP-1 receptor agonists are being studied for similar expanded uses, and have recently been approved for weight management and cardiovascular risk reduction.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05319APA
Cherney, David Z I; Udell, Jacob A; Drucker, Daniel J. (2021). Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.. Med (New York, N.Y.), 2(11), 1203-1230. https://doi.org/10.1016/j.medj.2021.10.004
MLA
Cherney, David Z I, et al. "Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.." Med (New York, 2021. https://doi.org/10.1016/j.medj.2021.10.004
RethinkPeptides
RethinkPeptides Research Database. "Cardiorenal mechanisms of action of glucagon-like-peptide-1 ..." RPEP-05319. Retrieved from https://rethinkpeptides.com/research/cherney-2021-cardiorenal-mechanisms-of-action
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.